(RTTNews) - Pacific Biosciences of California, Inc. (PACB), a life science technology company, reported preliminary fourth-quarter 2025 revenue growth of 14%, while full-year 2025 revenue rose 4%. The ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major ...

Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving ...

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and granted a non-exclusive license certain intellectual ...

Pacific Biosciences of California Inc. (NASDAQ:PACB) on Wednesday announced preliminary revenue of $36.9 million versus a consensus of $33.49 million. The company said the first quarter met ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 12 cents in third-quarter 2025, narrower than the year-ago adjusted loss of 17 cents ...

Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) ...

Children’s Mercy Kansas City is partnering with biotechnology company Pacific Biosciences of California and Microsoft on a genomic research and tech development project to combat rare diseases.